Table 1 Baseline characteristics of demographics, clinical and laboratory findings in Survivor group and Non-Survivor group

 Age, years

58.0 (46.0–69.0)

56.0 (42.0–65.0)

70.0 (62.0–82.0)

< 0.00

 Sex N (%)

1

  Male

189 (58%)

154 (57%)

35 (64%)

0.366

  Female

136 (42%)

116 (43%)

20 (37%)

Comorbidity N(%)

155 (48%)

117 (43%)

38 (69%)

0.001

Hypertension

98 (30%)

71 (26%)

27 (49%)

0.001

Coronary heart disease

31 (10%)

20 (7%)

11 (20%)

0.004

Chronic kidney disease

5 (2%)

2 (1%)

3 (6%)

0.036

Diabetes

38 (12%)

26 (10%)

12 (22%)

0.010

Chronic obstructive lung

10 (3%)

6 (2%)

4 (7%)

0.070

Stroke

16 (5%)

7 (3%)

9 (16%)

< 0.001

Carcinoma

10 (3%)

8 (3%)

2 (4%)

0.679

Other

61 (19%)

45 (17%)

16 (29%)

0.030

Temperature(°C),median(IQR)

37.0 (36.5–37.8)

37.0 (36.6,37.9)

36.6 (36.3–37.4)

0.014

Pulse(beats per min), median(IQR)

88 (80.0–97.0)

87.0 (80.0,96.0)

90.0 (80.3–99.5)

0.356

Respiratory rate(breaths per min), median(IQR)

20.0 (20.0–23.0)

20.0 (19.0,22.0)

23.0 (20.0–26.0)

< 0.001

Systolic blood pressure, median(IQR)

127.0 (117.0–138.0)

125.0 (115.0,138.0)

130.5 (127.3–146.5)

0.003

Diastolic blood pressure, median(IQR)

78.0 (70.0–85.0)

78.0 (70.0,85.0)

76.0 (65.8–85.0)

0.222

APACH II sore, median(IQR)

6.0 (4.0–9.0)

5.0 (3.0–7.0)

13.0 (9.0–29.0)

< 0.001

SOFA sore, median(IQR)

2.0 (2.0–4.0)

2.0 (1.0,3.0)

7.0 (4.0–14.0)

< 0.001

Clinical Classifications N (%)

< 0.001

 Severe type

222 (68%)

216 (80%)

6 (11%)

 Critical type

103 (32%)

54 (20%)

49 (89%)

 In-hospital days

20.0 (14.0–28.0)

20.0 (14.0–28.0)

15.0 (7.0–28.0)

0.003

Total course of disease ^a

28.0 (19.0–37.0)

27.0 (19.0–36.0)

30.0 (20.0–38.0)

0.345

 WBC, (1 × 109/L)

5.8 (4.2–8.3)

5.3 (4.1–7.1)

9.2 (5.6–15.7)

< 0.001

 NEU,(1 × 109/L)

3.9 (2.6–6.5)

3.6 (2.4–5.4)

8.1 (4.8–14.4)

< 0.001

 LYM,(1 × 109/L)

1.0 (0.6–1.4)

1.0 (0.7–1.5)

0.6 (0.4–0.8)

< 0.001

 MON,(1 × 109/L)

0.4 (0.3–0.6)

0.4 (0.3–0.6)

0.4 (0.2–0.6)

0.205

 PLT,(1 × 109/L)

178.0 (144.0–233.5)

186.0 (147.5–239.5)

153.0 (84.5–199.5)

< 0.001

 HGB,(g/L)

129.0 (117.0–141.0)

130.0 (119.5–142.5)

117.0 (94.0–133.5)

< 0.001

 FIB,(g/L)

4.1 (3.4–4.8)

4.1 (3.4–4.8)

3.9 (3.0–4.6)

0.340

 IL-6,(pg/ml)

19.1 (7.7–42.8)

16.0 (7.1–33.8)

66.9 (22.6–112.5)

< 0.001

 PCT,(ng/ml)

0.1 (0–0.2)

0.1 (0–0.1)

0.2 (0.1–0.4)

< 0.001

 CRP,(mg/L)

25.2 (8.7–63.6)

20.1 (7.9–46.3)

70.0 (34.9–150.5)

< 0.001

 ALT, (U/L)

24.0 (16.1–37.9)

24.0 (16.0–37.4)

25.8 (18.0–43.8)

0.378

 TBIL, (umol/L)

11.3 (7.9–15.6)

10.9 (7.5–15.0)

13.3 (10.2–20.1)

0.004

 DBIL, (umol/L)

3.7 (2.4–6.1)

3.5 (2.2–5.2)

5.8 (3.6–8.6)

< 0.001

 CREA, (μmol/L)

65.0 (52.5–80.9)

64.0 (52.0–80.0)

68.4 (55.3–104.8)

0.096

 Lac, (mmol/L)

1.6 (1.2–2.2)

1.5 (1.1–2.1)

1.9 (1.3–2.5)

0.077

 Pa0₂/FiO₂

237.9 (164.2–285.0)

247.3 (196.6–286.5)

143.3 (90.2–235.6)

< 0.001